Urologix, Inc. (ULGX) Reports Q4 Loss of $0.17/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Urologix Reports Fourth Quarter and Fiscal Year 2014 Results
August 19, 2014 4:00 PM EDTRecent Highlights
Urologix restructured the company in April 2014 which reduced cash utilization in the fourth quarter to $98,000 Cost-effectiveness data covering Cooled ThermoTherapyTM presented at 2014 AUA Annual Meeting in MayMINNEAPOLIS, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Urologix®, Inc. (OTCQB: ULGX), the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today reported financial results for its fourth quarter and fiscal year ended June 30, 2014. The Company also announces that Brian Smrdel, Chief Financial Officer, resigned due to personal reasons effective August 13, 2014.... More
